If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
8 June Observation of the axial Higgs mode, a Higgs boson-like excitation in a charge density wave material, is reported. It was incorrectly reported in some press releases as a dark matter particle. Scientists provide an overview of the capabilities of missions and observatories for detecting various alien technosignatures. 9 June A study estimates the air pollution impacts on climate change and the ozone layer from rocket launches and re-entry of reusable components and debris in 2019 and from a theoretical future space industry extrapolated from the "billionaire space race". It concludes that substantial effects from routine space tourism should "motivate regulation". Researchers report a robotic finger covered in a type of manufactured living human skin. Researchers demonstrate an electronic skin giving biological skin-like haptic sensations and touch/pain-sensitivity to a robotic hand (1 June). A system of an electronic skin and a human-machine interface is reported that can enable remote sensed tactile perception, and wearable or robotic sensing of many hazardous substances and pathogens (1 June). A multilayer tactile sensor hydrogel-based robot skin is demonstrated (8 June). 10 June – The core of the globular cluster NGC 3201 is shown to harbor a sub-cluster of nearly a hundred black holes. The same study also confirms that the globular cluster NGC 6397 has ejected most of its original black hole population, and its inner mass excess is composed by hundreds of massive white dwarfs.
Of the various methods of labeling biomolecules, fluorescent labels are advantageous in that they are highly sensitive even at low concentration and non-destructive to the target molecule folding and function. Green fluorescent protein is a naturally occurring fluorescent protein from the jellyfish Aequorea victoria that is widely used to tag proteins of interest. GFP emits a photon in the green region of the light spectrum when excited by the absorption of light. The chromophore consists of an oxidized tripeptide -Ser^65-Tyr^66-Gly^67 located within a β barrel. GFP catalyzes the oxidation and only requires molecular oxygen. GFP has been modified by changing the wavelength of light absorbed to include other colors of fluorescence. YFP or yellow fluorescent protein, BFP or blue fluorescent protein, and CFP or cyan fluorescent protein are examples of GFP variants. These variants are produced by the genetic engineering of the GFP gene. Synthetic fluorescent probes can also be used as fluorescent labels. Advantages of these labels include a smaller size with more variety in color. They can be used to tag proteins of interest more selectively by various methods including chemical recognition-based labeling, such as utilizing metal-chelating peptide tags, and biological recognition-based labeling utilizing enzymatic reactions. However, despite their wide array of excitation and emission wavelengths as well as better stability, synthetic probes tend to be toxic to the cell and so are not generally used in cell imaging studies.
=== tib-tie === tibalosin (INN) tibeglisene (INN) tibenelast (INN) tibenzate (INN) tibezonium iodide (INN) tibolone (INN) tibric acid (INN) tibrofan (INN) ticabesone (INN) ticagrelor (USAN) ticarbodine (INN) ticarcillin (INN) ticarcillin/clavulanic acid TICE BCG (Organon Teknika Corp) ticlatone (INN) Ticlid ticlopidine (INN) ticolubant (INN) tideglusib (INN) tidembersat (INN) tidiacic (INN) tiemonium iodide (INN) tienilic acid (INN) tienocarbine (INN) tienopramine (INN) tienoxolol (INN)
== Research == Bimatoprost has been used to treat eyebrow hypotrichosis in a 60-year old female. The 0.03% solution was applied topically once a day for eight months and showed "increased hair growth and thickening of the eyebrow hairs". Bimatoprost and its endogenous analog prostaglandin F2α ethanolamide present the side-effect of being anti-adipogenic, and have been shown to be inducers of preadipocyte proliferation. These findings suggest bimatoprost is a possible therapy for obesity.
The 2006 northwest Atlantic cod quota is 23,000 tons, representing half the available stocks, while the northeast Atlantic quota is 473,000 tons. Pacific cod is currently enjoying strong global demand. The 2006 total allowable catch (TAC) for the Gulf of Alaska and Aleutian Islands was 260,000 tons. In 2026, Canada increased the Northern cod quota by 55 per cent, from 38,000 tonnes to 59,000 tonnes.
Sources: en.wikipedia.org
== History == The first ion funnel was created in 1997 in the Environmental Molecular Sciences Laboratory Pacific Northwest National Laboratory by the researchers in Richard D. Smith's lab. The ion funnel was implemented to replace the ion transmission-limited skimmer for more efficient ion capture in an ESI source. Many characteristics of the ion funnel are attributed to the stacked ring ion guide, however, the disks of an ion funnel vary in diameter down its long axis. There is a portion at the base of the ion funnel in which a series of cylindrical ring electrodes have decreasing diameters, which enables the ion cloud entering the ion funnel to be spatially dispersed. This allows for efficient transfer of the ion cloud through the conductance limiting orifice at the exit as the ion cloud becomes focused to a much smaller radial size. The DC electric field serves to push ions through the funnel. For positive ions, the front plate of the funnel has the most positive DC voltage, and subsequent plates have gradually decreasing DC components, providing added control. RF and DC electric fields are co-applied with a pseudopotential created with alternating RF polarities on adjacent electrodes. This “pseudo-potential” radially confines ions and causes instability in ions with a lower m/z (mass to charge ratio) while ions with a higher m/z are focused to the center of the funnel. The initial ion funnel design used in the Smith research lab proved inefficient for collecting ions with low m/z.
Troika co-founder Jason Anderson's research on Vampire: The Masquerade source material and fansites found that the game's main attraction was character interaction and involvement in the vampire societies, not statistics and powers. Troika tried to remain faithful to the pen-and-paper role-playing game, hoping not to alienate the game's fans, but rules designed for multiple players did not translate well to single-player computer game design. The team attempted to discover which elements could work equally well in pen-and-paper and computer games. However, although much of the character system and attributes were translated, not all the attributes (such as "knowledge of law") made sense in the computer game. Of 30 pen-and-paper abilities, 15 reached the final design. Another difficult area was feats. Although common feats worked well, with a random chance of success or failure, uncommon ones would appear to fail more often. To avoid this, randomization was replaced by a degree of difficulty in accomplishing the feat. Although pen-and-paper falling damage is random, the computer game bases damage on the distance of the fall. The team's biggest challenge was adapting disciplines. The pen-and-paper version may require a little blood that requires a long time to use or have no blood cost and can be used at will; upgraded disciplines had additional requirements considered too confusing for a computer game.
Sulfonylureas or sulphonylureas are a class of organic compounds used in medicine and agriculture. The functional group consists of a sulfonyl group (-S(=O)2) with its sulphur atom bonded to a nitrogen atom of a ureylene group (N,N-dehydrourea, a dehydrogenated derivative of urea). The side chains R1 and R2 distinguish various sulfonylureas. In humans, sulfonylureas are medically used in the management of type 2 diabetes by stimulating insulin secretion. Sulfonylureas are the most widely used herbicide.
== Impact of narcotics trafficking == In the late 1980s, there continued to be concern about an overburdened and allegedly corrupt judicial system. According to the Department of State's Country Reports on Human Rights Practices for 1988 and Bolivian press reports, judges were implicated in drug-related corruption. Narcotics traffickers routinely tried to bribe judicial and other officials in exchange for releasing suspected smugglers, returning captured drugs, and purging incriminating files. In 1988 the Senate's Constitution and Justice Committee ordered the suspension of thirteen judges of the La Paz, Cochabamba, and Santa Cruz superior district courts of justice for wrongdoing in drug-trafficking cases. The Supreme Court of Justice insisted, however, on its prerogative to try the judges first. After doing so, it ordered the suspension of several of the accused judges and continued to investigate others. Relatively few prosecutions or forfeitures of traffickers' assets took place. A lack of judicial investigatory power hampered the investigation of the bank accounts and the origin of wealth of people suspected of trafficking in drugs. Although thirteen of the "big bosses" reportedly had been identified by early 1988, arrests of drug kingpins were infrequently reported because of lack of evidence.
The European Wound Management Association (EWMA) was founded in 1991. The association promotes the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. EWMA is an umbrella organisation linking wound management associations across Europe and a multidisciplinary group bringing together individuals and organisations interested in wound management. Currently, the association bridges 54 Cooperating Organisations (national wound care associations in Europe) and, in addition, partners with a considerable number of wound and wound related associations in and outside of Europe. Similar organizations include the European Tissue Repair Society, the Tissue Viability Society, the World Union of Wound Healing Societies, and the Wound Care Society. EWMA is an educational resource, organising conferences, contributing to international projects related to wound management, supporting the implementation of existing knowledge within wound management, and providing information on all aspects of wound management.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.